SCHEMBL536562

SCHEMBL536562

Cc1nc2ccccc2nc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
ALDH1A1 P00352 5/20 0.56
CYP1A2 P05177 3/20 0.56
KDM4E B2RXH2 2/20 0.56
HPGD P15428 2/20 0.54
GAA P10253 2/20 0.54
STAT3 P40763 1/20 0.54
GPR3 P46089 1/20 0.48
PDE10A Q9Y233 1/20 0.47
NQO2 P16083 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
ERN1 O75460 1/20 0.44
NUDT1 P36639 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22627551 0.84 ALDH1A1 (0.53) MAPTALDH1A1CYP1A2KDM4EHPGD
SCHEMBL23077792 0.84 MAPT (0.45) MAPTALDH1A1CYP1A2KDM4EHPGD
SCHEMBL29450004 0.81 MAPT (0.62) MAPTALDH1A1CYP1A2KDM4EHPGD
SCHEMBL11038905 0.81 MAPT (0.62) MAPTALDH1A1CYP1A2KDM4EHPGD
SCHEMBL103601 0.81 MAPT (0.62) MAPTALDH1A1CYP1A2KDM4EHPGD
SCHEMBL382385 0.81 MAPT (0.62) MAPTALDH1A1CYP1A2KDM4EHPGD
SCHEMBL29364974 0.81 MAPT (0.62) MAPTALDH1A1CYP1A2KDM4EHPGD
SCHEMBL11011451 0.78 MAPT (0.59) MAPTALDH1A1CYP1A2KDM4EHPGD
Water SCHEMBL27864881 0.78 MAPT (0.59) MAPTALDH1A1CYP1A2KDM4EHPGD
Ammonia Solution, Strong SCHEMBL27821564 0.78 MAPT (0.59) MAPTALDH1A1CYP1A2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117143086-A type-I bioactive photosensitizer targeting histone deacetylase, preparation method and application 上海市第一人民医院 2023-12-01 CN claimed
CN-108774183-A A kind of preparation method of ethylene glycol compounds 成都苑东生物制药股份有限公司 2018-11-09 CN claimed
WO-2007027460-A2 ANTISKINNING COMPOUND AND COMPOSITIONS CONTAINING THEM ARKEMA INC. (US) 2007-03-08 WO claimed
US-20070044689-A1 Antiskinning compound and compositions containing them ARKEMA INC. 2007-03-01 US claimed
EP-0939793-B1 STABILIZATION OF BIOCIDAL ACTIVITY IN AIR DRYING ALKYDS TROY TECHNOLOGY CORP INC (US) 2001-10-10 EP claimed
US-5955483-A HALOPROPARGYL AND CHELATE COMPOUND WITH TRANSITION METAL DRIER TROY TECHNOLOGY CORPORATION (US) 1999-09-21 US claimed
EP-0939793-A1 STABILIZATION OF BIOCIDAL ACTIVITY IN AIR DRYING ALKYDS TROY CORPORATION (US) 1999-09-08 EP claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 US claimed
US-5916930-A Stabilization of biocidal activity in air drying alkyds TROY CORPORATION (US) 1999-06-29 US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS 1998-12-30 WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed
WO-1998022543-A1 STABILIZATION OF BIOCIDAL ACTIVITY IN AIR DRYING ALKYDS TROY CORPORATION (US) 1998-05-28 WO claimed
US-20230322803-A1 SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER BRISTOL MYERS SQUIBB CO (US) 2023-10-12 US disclosed
CN-116583509-A Compounds and methods for treating cancer 上海睿跃生物科技有限公司 2023-08-11 CN disclosed
US-11465960-B2 Labile esters of agrochemicals for controlled release and reduction of off-site movement MONSANTO TECHNOLOGY LLC (US) 2022-10-11 US disclosed
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2022-02-17 US disclosed
US-5034530-A For treatment of central nervous system problems such as convulsions and anxiety NOVO NORDISK A/S (DK) 1991-07-23 US disclosed
EP-0347094-A1 Imidazoquinoxaline compounds and their preparation and use NOVO NORDISK A/S (DK) 1989-12-20 EP disclosed
US-4870171-A HYPOTENSIVE TOYO JOZO KABUSHIKI KAISHA (JP) 1989-09-26 US disclosed
EP-0304322-A1 1-Substituted alkyl-2-oxo-1,2-dihydroquinoxaline derivatives ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 1989-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11465960-B2 Labile esters of agrochemicals for controlled release and reduction of off-site movement APEH, GUSB, CES2 MAPT 2958/4885ALDH1A1 69/4885CYP1A2 39/4885
US-20220048890-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 MAPT 1932/4885ALDH1A1 3964/4885CYP1A2 4477/4885
US-20230322803-A1 SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER DDX21, HRAS, RPL17 MAPT 3829/4885ALDH1A1 1946/4885CYP1A2 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.